Related Experiment Video
Updated: Jan 30, 2026

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
Published on: November 22, 2024
Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment
Peter Kühnen1, Heiko Krude1, Heike Biebermann1
1Institute for Experimental Pediatric Endocrinology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Abstract:
The melanocortin-4 receptor (MC4R) - embedded in the leptin-melanocortin pathway - is activated by proopiomelanocortin (POMC)-derived neuropeptides such as α- and β-melanocyte-stimulating hormone (MSH) and plays an important role in hypothalamic body-weight regulation. Accordingly, MC4R is a potential drug target to combat obesity. Previous attempts to develop MC4R agonists failed due to ineffectiveness or severe adverse events. Recently, a new generation of MC4R ligands was developed. Specifically, setmelanotide was found to be effective by inducing biased signalling of the MC4R and thereby reducing feelings of hunger and leading to substantial weight loss in patients with POMC or leptin receptor deficiency. This new potential pharmacological treatment option could be beneficial for further groups of obese patients with defects in the leptin-melanocortin signalling pathway.
Insights
Setmelanotide, a novel melanocortin-4 receptor (MC4R) agonist, effectively treats obesity by reducing hunger and promoting weight loss. This biased signaling approach offers a promising new avenue for managing obesity in patients with specific genetic defects.
Area of Science:
- Endocrinology
- Neuroscience
- Pharmacology
Background:
- The melanocortin-4 receptor (MC4R) is crucial for hypothalamic body-weight regulation.
- MC4R is activated by proopiomelanocortin (POMC)-derived melanocyte-stimulating hormones (MSH).
- MC4R is a key drug target for obesity, but previous agonists had limitations.
Purpose of the Study:
- To evaluate the efficacy of a new generation of MC4R ligands.
- To investigate the potential of setmelanotide in treating obesity.
- To explore setmelanotide's biased signaling mechanism.
Main Methods:
- Development of novel MC4R ligands.
- Assessment of setmelanotide's efficacy in patients with POMC or leptin receptor deficiency.
- Analysis of MC4R biased signaling.
Main Results:
- Setmelanotide demonstrated effectiveness in inducing weight loss.
- Setmelanotide reduced feelings of hunger in treated patients.
- Biased signaling of MC4R by setmelanotide was observed.
Conclusions:
- Setmelanotide represents a new pharmacological option for obesity treatment.
- Biased signaling MC4R agonists offer a promising therapeutic strategy.
- Further investigation may extend setmelanotide's benefits to broader obese populations with leptin-melanocortin pathway defects.
Related Concept Videos
Signal Sequences and Sorting Receptors
Insulin: The Receptor and Signaling Pathways
Obesity
GTPases and their Regulation
Large G-proteins,...
What is Cell Signaling?
Intracellular Signaling Cascades

